<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01107405</url>
  </required_header>
  <id_info>
    <org_study_id>584</org_study_id>
    <nct_id>NCT01107405</nct_id>
  </id_info>
  <brief_title>Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge</brief_title>
  <official_title>Efficacy of Loteprednol Etabonate Ophthalmic Base Compared to Loteprednol Etabonate Ophthalmic Suspension vs Placebo in a Modified Conjunctival Allergen Challenge(CAC) Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of loteprednol etabonate ophthalmic
      base, compared to loteprednol etabonate ophthalmic suspension, and vehicle in the prevention
      of the signs and symptoms of allergic conjunctivitis in a modified Conjunctival Allergen
      Challenge model and in an environmental model during pollen season. Comparisons will be made
      following 2 weeks of dosing.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Itching</measure>
    <time_frame>Visit 4 (8 hr re-challenge)</time_frame>
    <description>Evaluated by subject at 3, 5, and 7 min post challenge on a scale of 0-4 where 0=no itching and 4=incapacitating itch.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conjunctival Redness</measure>
    <time_frame>Visit 4 (8 hr re-challenge)</time_frame>
    <description>Evaluated by investigator at 7, 15 and 20 minutes post challenge on a scale of 0-4 where 0= no redness and 4=extremely severe redness.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular Itching</measure>
    <time_frame>Visit 3 (initial challenge)</time_frame>
    <description>Evaluated by the subject at 3, 5 and 7 min post-challenge on a scale of 0-4 where 0=no itching and 4=incapacitating itch.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival Redness</measure>
    <time_frame>Visit 3 (initial challenge)</time_frame>
    <description>Evaluated by investigator at 7, 15 and 20 minutes post challenge on a scale of 0-4 where 0= no redness and 4=extremely severe redness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Itching</measure>
    <time_frame>Visit 4 (initial challenge)</time_frame>
    <description>Evaluated by the subject at 3, 5 and 7 min post-challenge on a scale of 0-4 where 0=no itching and 4=incapacitating itch.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival Redness</measure>
    <time_frame>Visit 4 (initial challenge)</time_frame>
    <description>Evaluated by investigator at 7, 15 and 20 minutes post challenge on a scale of 0-4 where 0= no redness and 4=extremely severe redness.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>Loteprednol etabonate base (QD)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Loteprednol etabonate ophthalmic base dosed once/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Loteprednol etabonate base (BID)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Loteprednol etabonate ophthalmic base dosed two times/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Loteprednol etabonate base (QID)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Loteprednol etabonate ophthalmic base dosed four times/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Loteprednol etabonate suspension (QID)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Loteprednol etabonate ophthalmic suspension dosed four times/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle of loteprednol etabonate</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle of loteprednol etabonate, dosed either QD, BID, or QID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loteprednol etabonate base (QD)</intervention_name>
    <description>Loteprednol Etabonate ophthalmic base once daily dosing for 2 weeks</description>
    <arm_group_label>Loteprednol etabonate base (QD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loteprednol etabonate base (BID)</intervention_name>
    <description>Loteprednol etabonate ophthalmic base BID dosing for 2 weeks</description>
    <arm_group_label>Loteprednol etabonate base (BID)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loteprednol etabonate base (QID)</intervention_name>
    <description>Loteprednol Etabonate ophthalmic base four times/day dosing for 2 week</description>
    <arm_group_label>Loteprednol etabonate base (QID)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loteprednol etabonate suspension</intervention_name>
    <description>Loteprednol etabonate ophthalmic suspension dosed four times daily for 2 weeks.</description>
    <arm_group_label>Loteprednol etabonate suspension (QID)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle of loteprednol etabonate</intervention_name>
    <description>Vehicle of loteprednol etabonate ophthalmic dosed once, twice or four times daily for 2 weeks.</description>
    <arm_group_label>Vehicle of loteprednol etabonate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive history of ocular allergies and positive skin test reaction to cat hair, cat
             dander, grasses, ragweed, and/or trees within the past 24 months.

          -  Calculated best-corrected visual acuity of 0.70 logMAR or better in each eye as
             measured using the ETDRS chart.

          -  Positive bilateral conjunctival allergen challenge(CAC)reaction within 10 minutes of
             instillation of the last titration of allergen at visit 1.

          -  Positive bilateral CAC reaction in 1 out of 3 time points for the initial and
             re-challenge at visit 2.

        Exclusion Criteria:

          -  Known contraindications or sensitivities to the study medication or its components.

          -  Any ocular condition that, in the opinion of the investigator, could affect the
             subjects safety or trial parameters.

          -  Use of disallowed medications during the period indicated prior to study enrollment or
             during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tuyen Ong, MD</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bausch &amp; Lomb</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2010</study_first_submitted>
  <study_first_submitted_qc>April 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2010</study_first_posted>
  <results_first_submitted>September 21, 2011</results_first_submitted>
  <results_first_submitted_qc>February 14, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 21, 2012</results_first_posted>
  <last_update_submitted>February 14, 2012</last_update_submitted>
  <last_update_submitted_qc>February 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loteprednol Etabonate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This 2 week ocular allergy study was conducted at 2 ophthalmology clinics in the United States. The first participant was enrolled on 4/22/2010 and the last participant visit was 5/30/2010.</recruitment_details>
      <pre_assignment_details>238 participants were screened, a total of 101 participants with seasonal and perennial allergy were randomized into the study. These 101 participants comprised the safety population, 90 of which completed the study. The ITT population was comprised of 97 subjects (4 excluded due to no post CAC-assessment).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Loteprednol Etabonate Base (QD)</title>
          <description>Loteprednol etabonate ophthalmic base dosed once/day.</description>
        </group>
        <group group_id="P2">
          <title>Loteprednol Etabonate Base (BID)</title>
          <description>Loteprednol etabonate ophthalmic base dosed two times/day</description>
        </group>
        <group group_id="P3">
          <title>Loteprednol Etabonate Base (QID)</title>
          <description>Loteprednol etabonate ophthalmic base dosed four times/day.</description>
        </group>
        <group group_id="P4">
          <title>Loteprednol Etabonate Suspension (QID)</title>
          <description>Loteprednol etabonate ophthalmic suspension dosed four times/day</description>
        </group>
        <group group_id="P5">
          <title>Vehicle of Loteprednol Etabonate</title>
          <description>Vehicle of loteprednol etabonate, dosed either QD, BID, or QID</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Loteprednol Etabonate Base (QD)</title>
          <description>Loteprednol etabonate ophthalmic base dosed once/day.</description>
        </group>
        <group group_id="B2">
          <title>Loteprednol Etabonate Base (BID)</title>
          <description>Loteprednol etabonate ophthalmic base dosed two times/day</description>
        </group>
        <group group_id="B3">
          <title>Loteprednol Etabonate Base (QID)</title>
          <description>Loteprednol etabonate ophthalmic base dosed four times/day.</description>
        </group>
        <group group_id="B4">
          <title>Loteprednol Etabonate Suspension (QID)</title>
          <description>Loteprednol etabonate ophthalmic suspension dosed four times/day</description>
        </group>
        <group group_id="B5">
          <title>Vehicle of Loteprednol Etabonate</title>
          <description>Vehicle of loteprednol etabonate, dosed either QD, BID, or QID</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="20"/>
            <count group_id="B5" value="20"/>
            <count group_id="B6" value="101"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=19 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 - 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ocular Itching</title>
        <description>Evaluated by subject at 3, 5, and 7 min post challenge on a scale of 0-4 where 0=no itching and 4=incapacitating itch.</description>
        <time_frame>Visit 4 (8 hr re-challenge)</time_frame>
        <population>Visit 4, Re-challenge Ocular Itching Scores – Primary Analysis ITT Population with LOCF included data from all randomized subjects who received treatment and had at least 1 post-CAC assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Loteprednol Etabonate Base (QD)</title>
            <description>Loteprednol etabonate ophthalmic base dosed once/day.</description>
          </group>
          <group group_id="O2">
            <title>Loteprednol Etabonate Base (BID)</title>
            <description>Loteprednol etabonate ophthalmic base dosed two times/day</description>
          </group>
          <group group_id="O3">
            <title>Loteprednol Etabonate Base (QID)</title>
            <description>Loteprednol etabonate ophthalmic base dosed four times/day.</description>
          </group>
          <group group_id="O4">
            <title>Loteprednol Etabonate Suspension (QID)</title>
            <description>Loteprednol etabonate ophthalmic suspension dosed four times/day</description>
          </group>
          <group group_id="O5">
            <title>Vehicle of Loteprednol Etabonate</title>
            <description>Vehicle of loteprednol etabonate, dosed either QD, BID, or QID</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Itching</title>
          <description>Evaluated by subject at 3, 5, and 7 min post challenge on a scale of 0-4 where 0=no itching and 4=incapacitating itch.</description>
          <population>Visit 4, Re-challenge Ocular Itching Scores – Primary Analysis ITT Population with LOCF included data from all randomized subjects who received treatment and had at least 1 post-CAC assessment.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="1.040"/>
                    <measurement group_id="O2" value="1.84" spread="0.978"/>
                    <measurement group_id="O3" value="1.82" spread="0.954"/>
                    <measurement group_id="O4" value="1.93" spread="0.794"/>
                    <measurement group_id="O5" value="2.68" spread="0.916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="1.036"/>
                    <measurement group_id="O2" value="2.13" spread="0.988"/>
                    <measurement group_id="O3" value="1.96" spread="0.960"/>
                    <measurement group_id="O4" value="2.12" spread="0.918"/>
                    <measurement group_id="O5" value="2.78" spread="0.924"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 Min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="1.035"/>
                    <measurement group_id="O2" value="2.03" spread="1.097"/>
                    <measurement group_id="O3" value="1.89" spread="0.993"/>
                    <measurement group_id="O4" value="2.04" spread="0.951"/>
                    <measurement group_id="O5" value="2.71" spread="0.899"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Conjunctival Redness</title>
        <description>Evaluated by investigator at 7, 15 and 20 minutes post challenge on a scale of 0-4 where 0= no redness and 4=extremely severe redness.</description>
        <time_frame>Visit 4 (8 hr re-challenge)</time_frame>
        <population>Visit 4, Re-challenge Conjunctival Hyperemia Scores, ITT Population with LOCF included data from all randomized subjects who received treatment and had at least 1 post-CAC assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Loteprednol Etabonate Base (QD)</title>
            <description>Loteprednol etabonate ophthalmic base dosed once/day.</description>
          </group>
          <group group_id="O2">
            <title>Loteprednol Etabonate Base (BID)</title>
            <description>Loteprednol etabonate ophthalmic base dosed two times/day</description>
          </group>
          <group group_id="O3">
            <title>Loteprednol Etabonate Base (QID)</title>
            <description>Loteprednol etabonate ophthalmic base dosed four times/day.</description>
          </group>
          <group group_id="O4">
            <title>Loteprednol Etabonate Suspension (QID)</title>
            <description>Loteprednol etabonate ophthalmic suspension dosed four times/day</description>
          </group>
          <group group_id="O5">
            <title>Vehicle of Loteprednol Etabonate</title>
            <description>Vehicle of loteprednol etabonate, dosed either QD, BID, or QID</description>
          </group>
        </group_list>
        <measure>
          <title>Conjunctival Redness</title>
          <description>Evaluated by investigator at 7, 15 and 20 minutes post challenge on a scale of 0-4 where 0= no redness and 4=extremely severe redness.</description>
          <population>Visit 4, Re-challenge Conjunctival Hyperemia Scores, ITT Population with LOCF included data from all randomized subjects who received treatment and had at least 1 post-CAC assessment.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" spread="0.620"/>
                    <measurement group_id="O2" value="1.99" spread="0.709"/>
                    <measurement group_id="O3" value="2.11" spread="0.649"/>
                    <measurement group_id="O4" value="2.16" spread="0.619"/>
                    <measurement group_id="O5" value="2.59" spread="0.501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread="0.660"/>
                    <measurement group_id="O2" value="2.13" spread="0.829"/>
                    <measurement group_id="O3" value="2.28" spread="0.766"/>
                    <measurement group_id="O4" value="2.18" spread="0.600"/>
                    <measurement group_id="O5" value="2.71" spread="0.597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" spread="0.720"/>
                    <measurement group_id="O2" value="2.06" spread="0.811"/>
                    <measurement group_id="O3" value="2.28" spread="0.691"/>
                    <measurement group_id="O4" value="2.16" spread="0.585"/>
                    <measurement group_id="O5" value="2.74" spread="0.592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Itching</title>
        <description>Evaluated by the subject at 3, 5 and 7 min post-challenge on a scale of 0-4 where 0=no itching and 4=incapacitating itch.</description>
        <time_frame>Visit 3 (initial challenge)</time_frame>
        <population>Visit 3 Ocular Itching Scores – ITT Population with LOCF included data from all randomized subjects who received treatment and had at least 1 post-CAC assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Loteprednol Etabonate Base (QD)</title>
            <description>Loteprednol etabonate ophthalmic base dosed once/day.</description>
          </group>
          <group group_id="O2">
            <title>Loteprednol Etabonate Base (BID)</title>
            <description>Loteprednol etabonate ophthalmic base dosed two times/day</description>
          </group>
          <group group_id="O3">
            <title>Loteprednol Etabonate Base (QID)</title>
            <description>Loteprednol etabonate ophthalmic base dosed four times/day.</description>
          </group>
          <group group_id="O4">
            <title>Loteprednol Etabonate Suspension (QID)</title>
            <description>Loteprednol etabonate ophthalmic suspension dosed four times/day</description>
          </group>
          <group group_id="O5">
            <title>Vehicle of Loteprednol Etabonate</title>
            <description>Vehicle of loteprednol etabonate, dosed either QD, BID, or QID</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Itching</title>
          <description>Evaluated by the subject at 3, 5 and 7 min post-challenge on a scale of 0-4 where 0=no itching and 4=incapacitating itch.</description>
          <population>Visit 3 Ocular Itching Scores – ITT Population with LOCF included data from all randomized subjects who received treatment and had at least 1 post-CAC assessment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" spread="0.829"/>
                    <measurement group_id="O2" value="2.00" spread="0.778"/>
                    <measurement group_id="O3" value="2.31" spread="0.889"/>
                    <measurement group_id="O4" value="2.28" spread="0.946"/>
                    <measurement group_id="O5" value="2.50" spread="1.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.45" spread="0.781"/>
                    <measurement group_id="O2" value="2.15" spread="0.745"/>
                    <measurement group_id="O3" value="2.46" spread="1.016"/>
                    <measurement group_id="O4" value="2.47" spread="0.979"/>
                    <measurement group_id="O5" value="2.63" spread="0.863"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" spread="0.872"/>
                    <measurement group_id="O2" value="2.21" spread="0.783"/>
                    <measurement group_id="O3" value="2.21" spread="1.044"/>
                    <measurement group_id="O4" value="2.38" spread="1.062"/>
                    <measurement group_id="O5" value="2.45" spread="0.810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Conjunctival Redness</title>
        <description>Evaluated by investigator at 7, 15 and 20 minutes post challenge on a scale of 0-4 where 0= no redness and 4=extremely severe redness.</description>
        <time_frame>Visit 3 (initial challenge)</time_frame>
        <population>Visit 3 Conjunctival Hyperemia Scores – ITT Population with LOCF included data from all randomized subjects who received treatment and had at least 1 post-CAC assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Loteprednol Etabonate Base (QD)</title>
            <description>Loteprednol etabonate ophthalmic base dosed once/day.</description>
          </group>
          <group group_id="O2">
            <title>Loteprednol Etabonate Base (BID)</title>
            <description>Loteprednol etabonate ophthalmic base dosed two times/day</description>
          </group>
          <group group_id="O3">
            <title>Loteprednol Etabonate Base (QID)</title>
            <description>Loteprednol etabonate ophthalmic base dosed four times/day.</description>
          </group>
          <group group_id="O4">
            <title>Loteprednol Etabonate Suspension (QID)</title>
            <description>Loteprednol etabonate ophthalmic suspension dosed four times/day</description>
          </group>
          <group group_id="O5">
            <title>Vehicle of Loteprednol Etabonate</title>
            <description>Vehicle of loteprednol etabonate, dosed either QD, BID, or QID</description>
          </group>
        </group_list>
        <measure>
          <title>Conjunctival Redness</title>
          <description>Evaluated by investigator at 7, 15 and 20 minutes post challenge on a scale of 0-4 where 0= no redness and 4=extremely severe redness.</description>
          <population>Visit 3 Conjunctival Hyperemia Scores – ITT Population with LOCF included data from all randomized subjects who received treatment and had at least 1 post-CAC assessment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.14" spread="0.584"/>
                    <measurement group_id="O2" value="2.05" spread="0.484"/>
                    <measurement group_id="O3" value="2.22" spread="0.593"/>
                    <measurement group_id="O4" value="2.25" spread="0.486"/>
                    <measurement group_id="O5" value="2.41" spread="0.663"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.26" spread="0.509"/>
                    <measurement group_id="O2" value="2.20" spread="0.737"/>
                    <measurement group_id="O3" value="2.28" spread="0.664"/>
                    <measurement group_id="O4" value="2.43" spread="0.415"/>
                    <measurement group_id="O5" value="2.42" spread="0.795"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" spread="0.541"/>
                    <measurement group_id="O2" value="2.24" spread="0.631"/>
                    <measurement group_id="O3" value="2.18" spread="0.706"/>
                    <measurement group_id="O4" value="2.33" spread="0.590"/>
                    <measurement group_id="O5" value="2.42" spread="0.834"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Itching</title>
        <description>Evaluated by the subject at 3, 5 and 7 min post-challenge on a scale of 0-4 where 0=no itching and 4=incapacitating itch.</description>
        <time_frame>Visit 4 (initial challenge)</time_frame>
        <population>Visit 4 Ocular Itching Scores – ITT Population with LOCF included data from all randomized subjects who received treatment and had at least 1 post-CAC assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Loteprednol Etabonate Base (QD)</title>
            <description>Loteprednol etabonate ophthalmic base dosed once/day.</description>
          </group>
          <group group_id="O2">
            <title>Loteprednol Etabonate Base (BID)</title>
            <description>Loteprednol etabonate ophthalmic base dosed two times/day</description>
          </group>
          <group group_id="O3">
            <title>Loteprednol Etabonate Base (QID)</title>
            <description>Loteprednol etabonate ophthalmic base dosed four times/day.</description>
          </group>
          <group group_id="O4">
            <title>Loteprednol Etabonate Suspension (QID)</title>
            <description>Loteprednol etabonate ophthalmic suspension dosed four times/day</description>
          </group>
          <group group_id="O5">
            <title>Vehicle of Loteprednol Etabonate</title>
            <description>Vehicle of loteprednol etabonate, dosed either QD, BID, or QID</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Itching</title>
          <description>Evaluated by the subject at 3, 5 and 7 min post-challenge on a scale of 0-4 where 0=no itching and 4=incapacitating itch.</description>
          <population>Visit 4 Ocular Itching Scores – ITT Population with LOCF included data from all randomized subjects who received treatment and had at least 1 post-CAC assessment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" spread="0.978"/>
                    <measurement group_id="O2" value="1.93" spread="1.130"/>
                    <measurement group_id="O3" value="2.04" spread="0.913"/>
                    <measurement group_id="O4" value="2.17" spread="0.846"/>
                    <measurement group_id="O5" value="2.55" spread="0.880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.19" spread="1.040"/>
                    <measurement group_id="O2" value="2.14" spread="1.071"/>
                    <measurement group_id="O3" value="2.15" spread="0.888"/>
                    <measurement group_id="O4" value="2.32" spread="0.853"/>
                    <measurement group_id="O5" value="2.82" spread="0.877"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="1.026"/>
                    <measurement group_id="O2" value="2.11" spread="0.985"/>
                    <measurement group_id="O3" value="2.13" spread="0.917"/>
                    <measurement group_id="O4" value="2.22" spread="0.953"/>
                    <measurement group_id="O5" value="2.71" spread="0.875"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Conjunctival Redness</title>
        <description>Evaluated by investigator at 7, 15 and 20 minutes post challenge on a scale of 0-4 where 0= no redness and 4=extremely severe redness.</description>
        <time_frame>Visit 4 (initial challenge)</time_frame>
        <population>Visit 4 Conjunctival Hyperemia Scores – ITT Population with LOCF included data from all randomized subjects who received treatment and had at least 1 post-CAC assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Loteprednol Etabonate Base (QD)</title>
            <description>Loteprednol etabonate ophthalmic base dosed once/day.</description>
          </group>
          <group group_id="O2">
            <title>Loteprednol Etabonate Base (BID)</title>
            <description>Loteprednol etabonate ophthalmic base dosed two times/day</description>
          </group>
          <group group_id="O3">
            <title>Loteprednol Etabonate Base (QID)</title>
            <description>Loteprednol etabonate ophthalmic base dosed four times/day.</description>
          </group>
          <group group_id="O4">
            <title>Loteprednol Etabonate Suspension (QID)</title>
            <description>Loteprednol etabonate ophthalmic suspension dosed four times/day</description>
          </group>
          <group group_id="O5">
            <title>Vehicle of Loteprednol Etabonate</title>
            <description>Vehicle of loteprednol etabonate, dosed either QD, BID, or QID</description>
          </group>
        </group_list>
        <measure>
          <title>Conjunctival Redness</title>
          <description>Evaluated by investigator at 7, 15 and 20 minutes post challenge on a scale of 0-4 where 0= no redness and 4=extremely severe redness.</description>
          <population>Visit 4 Conjunctival Hyperemia Scores – ITT Population with LOCF included data from all randomized subjects who received treatment and had at least 1 post-CAC assessment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" spread="0.755"/>
                    <measurement group_id="O2" value="2.19" spread="0.683"/>
                    <measurement group_id="O3" value="2.26" spread="0.661"/>
                    <measurement group_id="O4" value="2.22" spread="0.353"/>
                    <measurement group_id="O5" value="2.70" spread="0.445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.05" spread="0.793"/>
                    <measurement group_id="O2" value="2.19" spread="0.777"/>
                    <measurement group_id="O3" value="2.28" spread="0.717"/>
                    <measurement group_id="O4" value="2.36" spread="0.459"/>
                    <measurement group_id="O5" value="2.83" spread="0.479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" spread="0.777"/>
                    <measurement group_id="O2" value="2.16" spread="0.828"/>
                    <measurement group_id="O3" value="2.28" spread="0.701"/>
                    <measurement group_id="O4" value="2.29" spread="0.573"/>
                    <measurement group_id="O5" value="2.80" spread="0.544"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Loteprednol Etabonate Base (QD)</title>
          <description>Loteprednol etabonate ophthalmic base dosed once/day.</description>
        </group>
        <group group_id="E2">
          <title>Loteprednol Etabonate Base (BID)</title>
          <description>Loteprednol etabonate ophthalmic base dosed two times/day</description>
        </group>
        <group group_id="E3">
          <title>Loteprednol Etabonate Base (QID)</title>
          <description>Loteprednol etabonate ophthalmic base dosed four times/day.</description>
        </group>
        <group group_id="E4">
          <title>Loteprednol Etabonate Suspension (QID)</title>
          <description>Loteprednol etabonate ophthalmic suspension dosed four times/day</description>
        </group>
        <group group_id="E5">
          <title>Vehicle of Loteprednol Etabonate</title>
          <description>Vehicle of loteprednol etabonate, dosed either QD, BID, or QID</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Eye pruritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood oestrogen decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Temporomandibular joint syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngial pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Post nasal drip</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior to any presentation of results, draft versions of manuscripts will be made available to co-authors and to the Sponsor for review and comment. At least 30 days in the case of abstracts or 60 days in the case of full papers should be allowed for comments prior to submission for consideration of acceptance of presentation or publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tuyen Ong, MD MRCOphth</name_or_title>
      <organization>Bausch &amp; Lomb Incorporated</organization>
      <phone>(973) 360-6389</phone>
      <email>tuyen.ong@bausch.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

